GR1803 Injection in Patients With RRMM

Clinical trial NCT06952075 · RECRUITING

Trial details

NCT number: NCT06952075
Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Myleoma

Start date: 2025-04-24
Primary completion: 2027-07-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.